Latest Cambridge Antibody Technology Stories
Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug BenlystaÂ® (belimumab), approved today by the U.S. Food and Drug Administration. BenlystaÂ®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.
GAITHERSBURG, Md., Jan. 7, 2011 /PRNewswire/ -- MedImmune today announced an in-licensing agreement with Amgen for a novel monoclonal antibody targeting the IL-1 pathway.
THOUSAND OAKS, Calif. and MONROVIA, Calif., Jan. 6, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Xencor, Inc. announced today that they will collaborate to develop XmAb(Â®)5871, an Fc- engineered monoclonal antibody dually targeting CD19 and CD32b.
BURLINGAME, Calif., Dec. 7, 2010 /PRNewswire/ -- Apexigen, Inc. announced today that it has entered into a collaboration and worldwide license agreement with Centocor Research & Development, Inc.
THOUSAND OAKS, Calif., Nov 22, 2010 /PRNewswire/ -- ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that it has received a $244,479 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA).
GAITHERSBURG, Md., Nov. 16, 2010 /PRNewswire/ -- Today, MedImmune announced that researchers will present data from its oncology portfolio, including new clinical data, at two upcoming medical congresses in Europe and the United States.
PLANTATION, Fla., Oct. 18 /PRNewswire/ -- Goodwin Biotechnology, Inc., a full service contract biomanufacturing company, today announced that it has signed a new Biopharmaceutical Development and Manufacturing Agreement with a multinational biopharmaceutical client.
BURLINGAME, Calif., Aug. 12 /PRNewswire/ -- Epitomics, Inc.
BANNOCKBURN, Ill., Aug. 12 /PRNewswire/ -- The Board of Directors of Pinnacle Biologics Inc. has appointed Mr. James L. Foght PhD as a director of the corporation, effective July 28, 2010. Dr. Foght has over 40 years experience in the healthcare and life science industries.
LONDON, July 12, 2010 /PRNewswire/ -- MRC Technology (UK) announced today that it has entered into an agreement with Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for an exclusive licence to a series of small molecule drug candidates for the potential treatment of neurological disease. This is the first small molecule chemistry programme to come out of MRC Technology's Centre for Therapeutics Discovery (CTD) and the first major small molecule...
- Emitting flashes of light; glittering.